AbbVie (BUE:ABBV) Tax Provision: ARS-3,158,408 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ABBV AbbVie Inc BUE:ABBV
62 GF Score
Price ARS40,400.00
GF Value ARS33,481.73
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Tax Provision?

AbbVie BUE:ABBV -3.26% 62 Tax Provision is ARS-3,158,408 Mil as of Mar. 2026. GuruFocus rates BUE:ABBV with a GF Score™ of 62/100 and a GF Value™ of ARS33,481.73 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's tax provision for the three months ended in Mar. 2026 was ARS-478,200 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was ARS-3,158,408 Mil.

AbbVie Tax Provision Historical Data

* Premium members only.

The historical data trend for AbbVie's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Tax Provision Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -145,425.60 -273,604.79 -497,097.00 575,700.01 -3,431,319.97

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -396,565.74 -727,773.96 -714,314.52 -1,238,120.11 -478,199.82
BUE:ABBV
62GF Score
AbbVie Inc BUE:ABBV
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-3,158,408 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ARS-3,158,408 Mil mean?
AbbVie (BUE:ABBV) has a Tax Provision of ARS-3,158,408 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on AbbVie and its competitors.
Is AbbVie's Tax Provision too high?
AbbVie's current Tax Provision is ARS-3,158,408 Mil. Overall, AbbVie has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Tax Provision compare to MRK and JNJ?
AbbVie's Tax Provision of ARS-3,158,408 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on AbbVie and its competitors. AbbVie's current Tax Provision is ARS-3,158,408 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (BUE:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS33,481.73, compared to a current price of ARS40,400.00 — trading 20.7% above its estimated fair value. The current Tax Provision is ARS-3,158,408 Mil. AbbVie's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For AbbVie (BUE:ABBV), the current Tax Provision is ARS-3,158,408 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (BUE:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of ARS40,400.00 is trading 20.7% above its estimated GF Value™ of ARS33,481.73. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for BUE:ABBV:

  • Tax Provision: ARS-3,158,408 Mil
  • GF Value™: ARS33,481.73 vs. price of ARS40,400.00 (20.7% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the BUE:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
62GF Score

Get the complete analysis for BUE:ABBV

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS40,400.00
Price
ARS33,481.73
GF Value